primer sequences gambogenic acid  (MedChemExpress)

Journal: Frontiers in Cell and Developmental Biology

Article Title: Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells

doi: 10.3389/fcell.2021.734287

Figure Lengend Snippet: Immunohistochemistry (IHC) data of AURKA and EZH2 from the Human Protein Atlas. Higher expression of AURKA and EZH2 by immunohistochemistry in HCC compared with normal tissue.

Article Snippet: The EZH2 inhibitor gambogenic acid was purchased from MCE (Shanghai, China).

Techniques: Immunohistochemistry, Expressing

Journal: Frontiers in Cell and Developmental Biology

Article Title: Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells

doi: 10.3389/fcell.2021.734287

Figure Lengend Snippet: Gambogenic acid (EZH2 inhibitor) and alisertib (AURKA inhibitor) inhibit HCC cell proliferation, migration, and invasion. (A) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor) or alisertib (AURKA inhibitor) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (B) Hep3B and Huh7 cells were treated with DMSO (solvents of gambogenic acid and alisertib) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein-AM/PI staining assays. (C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein-AM/PI staining assays. (D) Colony formation assays were conducted to analyze Hep3B and Huh7 cell proliferation with gambogenic acid (2 μM) or alisertib (10 μM) treatment. ( E-F) Wound healing assays (E) and Transwell assays (F) were performed to detect the cell migratory abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). (G) Transwell assays were performed to detect the cell invasion abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). Data are expressed as the means ± s.d. Differences were considered statistically significant if p < 0.05. ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001. (H, I) Expression of AURKA (H) and EZH2 (I) in TCGA-LIHC based on TP3 mutation status.

Article Snippet: The EZH2 inhibitor gambogenic acid was purchased from MCE (Shanghai, China).

Techniques: Migration, Staining, IF-P, Expressing, Mutagenesis